Fresita Proteins Ltd (519242)
சுருக்கம்
நிகழ்வுகள்
- சமீபத்திய முடிவுகள்
- Q2 FY27, தாக்கல் செய்யப்பட்டது 30 அக். 2026
- இயக்குநர் குழுக் கூட்ட அறிவிப்பு
- 26 அக். 2026
பங்குச் சந்தைத் தரவு. ஒவ்வொரு எண்ணும் அதன் சொந்தப் பக்கம் காட்டும் வடிவத்திலேயே; தேதிகள் தரவின் தேதிகள். தகவலுக்கு மட்டுமே, முதலீட்டு ஆலோசனை அல்ல.
📈 பங்கு விலை & நிகழ்வுகள்
Q2 FY27 முடிவுகள்
Fresita Proteins Ltd reported Q2 FY27 results on 30 Oct 2026: revenue ₹0.8 Cr (-81.2% year on year, -93.8% on the previous quarter), and net profit ₹0.1 Cr (-65.1% year on year); the operating margin was 23.4%.
| Q2 FY27 (₹ கோடி) | மதிப்பு | YoY Q2 FY26-உடன் | QoQ |
|---|---|---|---|
| வருவாய் | ₹0.8 | -81.2% | -93.8% |
| செயல்பாட்டு லாபம் | ₹0.2 | -34.7% | நஷ்டத்திலிருந்து |
| நிகர லாபம் | ₹0.1 | -65.1% | -91.6% |
| EPS (₹) | 0.16 | -93.1% | -91.4% |
| செயல்பாட்டு லாப வரம்பு | 23.4% | — | — |
- செயல்பாட்டு லாப வரம்பு 1664 bps YoY அதிகரித்தது
- லாபம் இருந்தும் FY26-இல் செயல்பாட்டுப் பணப்புழக்கம் எதிர்மறையாக இருந்தது
- லாபம் இருந்தும் H1 FY27 செயல்பாட்டுப் பணப்புழக்கம் எதிர்மறையாக இருந்தது
லாபத்தின் தரம்: வரிக்கு முந்தைய ₹0.2 கோடி லாபத்தில், ₹0.2 கோடி (100%) முக்கிய வணிகத்திலிருந்து வந்தது; மீதம் பிற வருமானம் மற்றும் ஒருமுறை வரவுகளிலிருந்து வந்தது. முக்கிய லாபம் (செயல்பாட்டு லாபத்தில் வட்டி மற்றும் தேய்மானத்தைக் கழித்தது) YoY அடிப்படையில் -34.7% மாறியுள்ளது.
📢 சமீபத்திய கார்ப்பரேட் அறிவிப்புகள்
Fresita Proteins reported standalone revenue from operations of Rs 81.03 lakh for Q2 FY27 (ended September 30, 2026), marking an 81% decline from Rs 430.38 lakh in Q2 FY26 and a steep drop from Rs 1,299.30 lakh in Q1 FY27. Net profit for the quarter stood at Rs 13.95 lakh, down 65.5% YoY compared to Rs 40.46 lakh in the prior-year period. Notably, the company reported operating in only one segment: 'Renewable Energy Sector Solar Module Products'. The Board also approved shifting its registered office from Alwar, Rajasthan to Rajkot, Gujarat, subject to shareholder approval.
- Revenue from operations fell 81.2% YoY to Rs 81.03 lakh in Q2 FY27 from Rs 430.38 lakh in Q2 FY26
- Net profit declined 65.5% YoY to Rs 13.95 lakh compared to Rs 40.46 lakh in Q2 FY26
- H1 FY27 revenue stood at Rs 1,380.33 lakh with a net profit of Rs 179.91 lakh (reversing a loss of Rs 8.88 lakh in H1 FY26)
- Significant balance sheet items as of September 30, 2026 include Trade Receivables of Rs 2,477.21 lakh and Short Term Loans of Rs 7,258.96 lakh
- Approved shifting of registered office from Alwar (Rajasthan) to Rajkot (Gujarat)
Fresita Proteins Ltd (formerly Sarda Proteins Ltd) has filed its Letter of Offer for a Rights Issue to raise up to ₹89.76 crore. The company is offering up to 74,79,917 shares at ₹120 per share (face value ₹10 plus premium of ₹110) in the ratio of 5 rights shares for every 6 existing shares held on the record date of October 30, 2026. The proposed fundraise is massive relative to the company's size, representing ~117% of its current market capitalization of ₹77 crore. The issue opens on November 12, 2026, and closes on November 26, 2026.
- Issue size of up to 74,79,917 equity shares aggregating to ₹8975.90 Lakhs (₹89.76 cr)
- Issue price set at ₹120 per share (₹10 face value + ₹110 premium) vs current market price of ₹124.2
- Rights entitlement ratio of 5 rights shares for every 6 fully paid-up shares held
- Record date fixed as Friday, October 30, 2026
- Issue opens on November 12, 2026, and closes on November 26, 2026
Fresita Proteins has finalized terms for a Rights Issue aggregating up to ₹89.76 crore by offering 74,79,917 equity shares at ₹120 per share (including ₹110 premium). The issue is structured in an entitlement ratio of 5 rights equity shares for every 6 shares held, with a Record Date set for October 30, 2026. The proposed fundraise is massive relative to the company's existing scale, representing ~117% of its current market cap of ₹77 crore. The subscription window opens on November 12, 2026, and closes on November 26, 2026.
- Rights issue size of up to ₹89,75,90,000 (₹89.76 crore) through 74,79,917 shares
- Issue price set at ₹120 per share, a narrow discount to the latest price of ₹124.2
- Entitlement ratio fixed at 5 rights shares for every 6 existing shares held
- Record date determined as Friday, October 30, 2026
- Total outstanding equity shares to expand from 89,75,900 to 1,64,55,817 post-issue
Fresita Proteins Limited has scheduled a Rights Issue Committee meeting on October 26, 2026, to determine the final terms of its proposed rights issue. The fundraise was previously approved by the Board on August 5, 2026, for an amount not exceeding ₹90 Crore. The committee will decide the issue price, entitlement ratio, record date, and issue timing. The ₹90 Crore size is massive compared to the company's current market capitalization of ₹77 Crore (117%) and TTM revenue of ₹18 Crore (500%).
- Rights Issue Committee meeting scheduled for Monday, October 26, 2026.
- Proposed Rights Issue size is an amount not exceeding ₹90 Crore.
- Issue entails equity shares of face value ₹10 each.
- Meeting to finalize issue price, rights entitlement ratio, and record date.
Sarda Proteins Ltd has scheduled a Board of Directors meeting on Monday, September 7, 2026. The agenda includes approving and fixing the date, time, venue, and notice for the upcoming Annual General Meeting (AGM). The Board will also finalize the book closure dates and appoint a scrutinizer for remote e-voting. This is a routine administrative compliance filing with no immediate operational or financial impact.
- Board meeting scheduled for Monday, September 7, 2026
- Agenda to finalize day, date, time, and mode for the Annual General Meeting (AGM)
- Board to approve dates for closure of Register of Members and Share Transfer Books
- Appointment of a scrutinizer for remote e-voting and e-voting during AGM
Sarda Proteins has approved a significant fundraise through a Rights Issue of equity shares for an amount not exceeding ₹100 crore. This proposed issue size is substantial, representing approximately 116% of the company's reported net worth of ₹86 crore. Simultaneously, the company announced the resignation of Non-Executive Director Mr. Gunvantray Jayantilal Zaladi, effective August 5, 2026. A Rights Issue Committee has been formed to oversee the process, including the filing of the Draft Letter of Offer with SEBI.
- Approved a Rights Issue of equity shares for a total amount not exceeding ₹100 crore
- Proposed fundraise of ₹100 crore exceeds the company's current net worth of ₹86 crore
- Resignation of Non-Executive Director Mr. Gunvantray Jayantilal Zaladi effective August 5, 2026
- Board meeting concluded within 45 minutes (4:30 PM to 5:15 PM) to approve these measures
- Company to separately intimate the Record Date upon finalization of the Draft Letter of Offer
Sarda Proteins Ltd has issued revised audited financial results for FY26 to correct clerical errors involving interest income and the reclassification of share warrants as equity. For the full year ended March 31, 2026, the company reported a total revenue of Rs 16.51 Cr, representing a 31.7% decline from Rs 24.19 Cr in FY25. Despite the revenue drop, net profit improved to Rs 0.45 Cr from a near-break-even Rs 0.005 Cr in the previous year. The Q4 FY26 performance was bolstered by other income of Rs 24.36 Lakhs, leading to a quarterly profit of Rs 0.686 Cr.
- Total Revenue for FY26 declined to Rs 16.51 Cr from Rs 24.19 Cr in FY25.
- Net Profit for FY26 stood at Rs 45.44 Lakhs compared to Rs 0.50 Lakhs in FY25.
- Paid-up Equity Share Capital increased significantly to Rs 89.76 Lakhs from Rs 17.26 Lakhs due to warrant reclassification.
- Q4 FY26 Revenue from operations was minimal at Rs 0.65 Cr compared to Rs 15.26 Cr in the preceding half-year period.
- The company reported zero finance costs and zero debt as per the provided financial context.
Sarda Proteins has scheduled a Board Meeting for August 05, 2026, to evaluate various fund-raising options. The company is considering multiple instruments including equity shares, convertible bonds, debentures, and warrants. Potential routes for this capital infusion include rights issues, private placements, preferential issues, or Qualified Institutions Placements (QIP). As of the announcement on July 31, 2026, the specific quantum of funds to be raised and the intended use of proceeds remain undisclosed.
- Board meeting scheduled for August 05, 2026, to approve fund raising.
- Multiple instruments under consideration including equity, convertible bonds, and warrants.
- Permissible modes include Rights Issue, Private Placement, and QIP.
- Announcement made on July 31, 2026, following a 32.3% price return over the last 6 months.
Sarda Proteins Ltd has issued a revised outcome for its board meeting held on July 4, 2026. The board approved a proposal to change the company's name from "Sarda Proteins Limited" to a new name, which is currently pending approval from the Central Registration Centre (CRC) and the Ministry of Corporate Affairs. This update was filed on July 22, 2026, to include the agenda item that was omitted from the original disclosure.
- Board meeting held on July 4, 2026, commenced at 3:00 p.m. and concluded at 5:40 p.m.
- Revised outcome filed on July 22, 2026, to rectify an omission in the previous filing.
- Proposed name change requires approval from the Ministry of Corporate Affairs (MCA).
- Consequent alteration of the Memorandum of Association (MoA) and Articles of Association (AoA) approved.
Sarda Proteins has issued an addendum to its July 30, 2026, Extraordinary General Meeting (EGM) notice to include three new resolutions. The company is seeking shareholder approval to appoint M/s A H Mandaliya & Associates as statutory auditors for a five-year term (FY 2026-27 to FY 2030-31) following a casual vacancy. Additionally, the board has proposed the regularization of Ms. Minal Surendra Jain as a Woman Independent Director for a five-year term effective July 15, 2026. These items were finalized during a board meeting held on July 15, 2026.
- EGM scheduled for July 30, 2026, at 11:00 A.M. via Video Conferencing
- Proposed 5-year term for M/s A H Mandaliya & Associates as Statutory Auditors ending March 31, 2031
- Appointment of Ms. Minal Surendra Jain, age 26, as a Woman Independent Director for a 5-year term
- Casual vacancy for auditor was originally addressed by a board resolution dated November 26, 2025
Sarda Proteins reported a sharp turnaround in Q1 FY27, posting a net profit of ₹165.97 Lakhs compared to a loss of ₹49.34 Lakhs in the year-ago period. Revenue from operations grew 18.6% YoY to ₹1,299.30 Lakhs, while 'Other Income' saw a massive spike to ₹548.10 Lakhs. Crucially, the company disclosed it now operates solely in the 'Renewable Energy Sector Solar Cell Products' segment, a major shift from its historical edible oil focus. The board also established a new corporate office in Rajkot and appointed an Independent Women Director.
- Net Profit of ₹165.97 Lakhs in Q1 FY27 vs a loss of ₹49.34 Lakhs in Q1 FY26
- Revenue from operations increased to ₹1,299.30 Lakhs from ₹1,095.46 Lakhs YoY
- Other Income surged to ₹548.10 Lakhs, contributing significantly to the bottom line
- Business segment officially transitioned to Renewable Energy Sector Solar Cell Products
- Appointment of Ms. Minal Surendra Jain as Independent Women Director for a 5-year term
Sarda Proteins reported a significant turnaround in Q1 FY27, posting a net profit of ₹165.97 Lakhs compared to a loss of ₹49.34 Lakhs in the same quarter last year. Revenue from operations grew 18.6% YoY to ₹1,299.30 Lakhs, while total revenue reached ₹1,847.40 Lakhs, significantly aided by ₹548.10 Lakhs in other income. The company also announced the establishment of a new corporate office in Rajkot, Gujarat, and the appointment of an Independent Women Director for a 5-year term. Notably, the company now identifies its primary segment as 'Renewable Energy Sector Solar Cell Products'.
- Reported a Net Profit of ₹165.97 Lakhs in Q1 FY27, reversing a loss of ₹49.34 Lakhs in Q1 FY26.
- Revenue from operations increased to ₹1,299.30 Lakhs from ₹1,095.46 Lakhs in the corresponding quarter last year.
- Other income surged to ₹548.10 Lakhs, representing nearly 30% of total revenue for the quarter.
- Established a new Corporate Office in Rajkot, Gujarat, effective July 15, 2026.
- Appointed Ms. Minal Surendra Jain as an Independent Women Director for a 5-year term.
Sarda Proteins reported a significant turnaround in Q1 FY27, posting a net profit of ₹165.97 Lakhs compared to a loss of ₹49.34 Lakhs in the same quarter last year. Revenue from operations grew 18.6% YoY to ₹1,299.30 Lakhs, while total revenue was further bolstered by a sharp increase in other income to ₹548.10 Lakhs. The company also announced the establishment of a new corporate office in Rajkot, Gujarat, and the appointment of an Independent Women Director. Notably, the company now identifies its primary segment as 'Renewable Energy Sector Solar Cell Products', indicating a shift from its historical edible oil focus.
- Net profit of ₹165.97 Lakhs in Q1 FY27 vs a loss of ₹49.34 Lakhs in Q1 FY26.
- Revenue from operations increased to ₹1,299.30 Lakhs from ₹1,095.46 Lakhs YoY.
- Other income surged to ₹548.10 Lakhs from just ₹0.08 Lakhs in the previous year's quarter.
- Established a new Corporate Office in Rajkot, Gujarat, effective July 15, 2026.
- Appointed Ms. Minal Surendra Jain as an Independent Women Director for a 5-year term.
நிறுவனச் சுயவிவரம்
நிதிச் செயல்திறன்
இந்த நிறுவனத்துக்கான நிதிப் பகுப்பாய்வுத் தரவு இன்னும் கிடைக்கவில்லை.
செயல்பாட்டு உந்துசக்திகள்
இந்த நிறுவனத்திற்கான செயல்பாட்டுப் பகுப்பாய்வுத் தரவு இன்னும் கிடைக்கவில்லை.
வியூக வளர்ச்சி
இந்த நிறுவனத்துக்கான வியூக வளர்ச்சிப் பகுப்பாய்வு இன்னும் கிடைக்கவில்லை.
வெளிப்புறக் காரணிகள்
இந்த நிறுவனத்துக்கு வெளிப்புறக் காரணிகளின் பகுப்பாய்வு இன்னும் கிடைக்கவில்லை.
ஒழுங்குமுறை & நிர்வாகம்
இந்த நிறுவனத்திற்கான ஒழுங்குமுறைப் பகுப்பாய்வு இன்னும் கிடைக்கவில்லை.
அபாயப் பகுப்பாய்வு
இந்நிறுவனத்துக்கான அபாய பகுப்பாய்வு இன்னும் கிடைக்கவில்லை.
